Shares of Teva Pharmaceutical Industries Limited American Depositary Shares (NYSE:TEVA) traded at a new 52-week low today of $8.24. Approximately 8.3 million shares have changed hands today, as compared to an average 30-day volume of 8.4 million shares.
Over the past year, Teva Pharmaceutical Industries Limited American Depositary Shares has traded in a range of $8.24 to $13.30 and is now at $8.43.
Teva Pharmaceutical Industries Limited American Depositary Shares has overhead space with shares priced $8.43, or 3.6% below the average consensus analyst price target of $8.74.
Headquartered in Israel, Teva Pharmaceutical is the largest generic drug manufacturer in the world. The company was formed in 1901 and has a portfolio of more than 3,500 medicines–roughly 1 out of 9 generic prescriptions in the U.S. is filled with a Teva product. The company also develops branded pharmaceuticals in the central nervous system, oncology, and respiratory categories. Teva’s generic drug sales represent slightly over half of total revenue, with branded drug and distribution revenue making up the balance. Teva is an aggressive filer to bring generic drugs to market when brand patents expire and has the most generic products pending Food and Drug Administration approval.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer